Related Topics
Once a malaria patient, student now has sights set on stopping the deadly disease
Cyrianne Keutcha, PhD ’25, has been around malaria all her life, from growing up in a malaria-endemic country, to being infected herself, and now to studying the parasite in the lab.
Age, sex may be important to consider in assessing tuberculosis risk
How an individual’s immune system responds to the bacteria that causes tuberculosis—and therefore whether they develop the disease—may differ across age and sex, according to a new study co-led by Harvard Chan School’s Sarah Fortune.
Racial, ethnic disparities persist in U.S. tuberculosis cases
Racial and ethnic disparities in tuberculosis incidence persist among the U.S.-born population, according to a new study led by Harvard Chan School.
Migrant children in U.S. detention face physical, mental harms: report
Children detained for a prolonged period in family immigration detention centers in the U.S. are experiencing mental and physical harm due to inadequate and inappropriate medical care, according to a new report.
Botswana lab known for identifying Omicron variant receives new recognition
When the lab of the Botswana Harvard AIDS Institute Partnership produced the first genetic sequence of the Omicron variant of the coronavirus in fall 2021, the world took notice. More recognition came last month when the lab was…
Fighting antibiotic resistance
Because antibiotic resistance can threaten the success of treatments across a wide range of conditions, more work needs to be done to prevent it, according to Bill Hanage of Harvard Chan School.
Science fueled by social justice
Sydney Stanley, PhD ’23, researches infectious diseases with an eye toward improving the health of the world’s most vulnerable populations
New TB vaccine could produce large health, economic benefits in LMICs
Introducing an effective new tuberculosis vaccine in low- and middle-income countries could lead to billions of dollars in potential health and economic benefits, according to a modeling study led by Harvard Chan School.
Report makes the case for new TB vaccines
Investing more financial resources to accelerate scientific progress toward an effective tuberculosis vaccine will save lives, fight antimicrobial resistance, advance health equity, improve economic growth, and bring a substantial return on investment, according to a new report.
Failure of tuberculosis treatment linked to bacterial resilience
Researchers have discovered a new form of altered drug susceptibility—dubbed antibiotic resilience—that enables Mycobacterium tuberculosis to survive antibiotic treatment.
